Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.
Trahair TN, Lock RB, Sutton R, Sia KC, Evans K, Richmond J, Law T, Venn NC, Irving JA, Moore S, Nievergall E, Dang P, Heatley SL, White DL, Revesz T. Trahair TN, et al. Among authors: sia kc. Bone Marrow Transplant. 2016 Sep;51(9):1279-82. doi: 10.1038/bmt.2016.122. Epub 2016 May 16. Bone Marrow Transplant. 2016. PMID: 27183096 No abstract available.
Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.
Dolai S, Sia KC, Robbins AK, Zhong L, Heatley SL, Vincent TL, Hochgräfe F, Sutton R, Kurmasheva RT, Revesz T, White DL, Houghton PJ, Smith MA, Teachey DT, Daly RJ, Raftery MJ, Lock RB. Dolai S, et al. Among authors: sia kc. Cancer Res. 2016 May;76(9):2766-2777. doi: 10.1158/0008-5472.CAN-15-2786. Epub 2016 Mar 9. Cancer Res. 2016. PMID: 26960974 Free PMC article.
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S, Bracken LS, Harvey RC, Sia KC, Carol H, Chen IM, Evans K, Dietrich PA, Roberts KG, Kurmasheva RT, Billups CA, Mullighan CG, Willman CL, Loh ML, Hunger SP, Houghton PJ, Smith MA, Lock RB. Suryani S, et al. Among authors: sia kc. Mol Cancer Ther. 2015 Feb;14(2):364-74. doi: 10.1158/1535-7163.MCT-14-0647. Epub 2014 Dec 10. Mol Cancer Ther. 2015. PMID: 25504635 Free PMC article.
Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW, Sia KCS, Jones C, Evans K, Mariana A, Pang I, Failes T, Zhong L, Mayoh C, Landman R, Collins R, Erickson SW, Arndt G, Raftery MJ, Wilkins MR, Norris MD, Haber M, Marshall GM, Lock RB. Bӧhm JW, et al. Among authors: sia kcs. Leukemia. 2021 Nov;35(11):3101-3112. doi: 10.1038/s41375-021-01248-8. Epub 2021 Apr 24. Leukemia. 2021. PMID: 33895784
A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
Mohamed SMA, Wohlmann A, Schofield P, Sia KCS, McCalmont H, Savvides SN, Verstraete K, Kavallaris M, Christ D, Friedrich KH, Bayat N, Lock RB. Mohamed SMA, et al. Among authors: sia kcs. Int J Biol Macromol. 2021 Nov 1;190:214-223. doi: 10.1016/j.ijbiomac.2021.08.194. Epub 2021 Sep 2. Int J Biol Macromol. 2021. PMID: 34481852
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW. Waibel M, et al. Among authors: sia kc. Cell Rep. 2013 Nov 27;5(4):1047-59. doi: 10.1016/j.celrep.2013.10.038. Epub 2013 Nov 21. Cell Rep. 2013. PMID: 24268771 Free PMC article.
36 results